Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYLOX-1
2020-003087-45Phase 2Completed
- Sponsor
- Galecto, Inc.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenumlostat in myelofibrosis (MF), primary myelofibrosis (PMF) and secondary myelofibrosis (SMF), sponsored by Galecto, Inc. Primary endpoint: Safety and tolerability. Started Nov 2020; status: completed.
02
Drugs
lenumlostat
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)secondary myelofibrosis (SMF)
Beyond the preview
Go deeper on 2020-003087-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003087-45.